NCT05674305View on ClinicalTrials.gov

Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy

PHASE3RecruitingINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2027

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Radiotherapy

IMRT for primary and regional field

DRUG

Cisplatin

Cisplatin 80mg/m2, 21days/cycle, 2 cycles

Trial Locations (1)

200032

RECRUITING

Fudan Universtiy Shanghai Cancer Centre, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER